Objective To investigate effect of different resuscitation liquids and different resuscitation methods on contents of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in early resuscitation process of rats with traumatic hemorrhagic shock. Methods Sixty-four healthy SD rats (450–550 g) were chosen and divided into 4 groups randomly and averagely: crystal liquid limited resuscitation group, colloidal liquid limited resuscitation group, 7.5% NaCl limited resuscitation group, and colloidal liquid non-limited resuscitation group. There were 16 rats in each group. All the experimental rats were weighed before intraperitoneal injection of pentobarbital sodium anesthesia. Animal model was established via Chaudry’s method. The rats were killed and the abdominal aorta bloods were drew on hour 2, 6, 12, and 24 after recovering from anesthesia. The contents of IL-8 and TNF-α in plasmas were detected by enzyme linked immunosorbent assay. Results The contents of IL-8 and TNF-α among three kinds of limited resuscitation groups on hour 6 after resuscitation were significantly higher than those on hour 2 after resuscitation (P<0.05) and reached the peaks, then began to decrease. On hour 12 after resuscitation, the contents of IL-8 and TNF-α were decreased continuously among three kinds of limited resuscitation groups (P<0.05). The contents of IL-8 and TNF-α in the colloidal liquid non-limited resuscitation group at each point time were significantly higher than those among three kinds of limited resuscitation groups (P<0.05), which in the crystal liquid resuscitation group were significantly lower than those in the other limited liquid resuscitation groups (P<0.05). Conclusions In process of liquid resuscitation of rats with traumatic hemorrhagic shock, limited resuscitation method is better than that of non-limited resuscitation method. Among three kinds of limited resuscitation methods, crystal resuscitation liquid is more effective than the other two resuscitation liquids in prohibiting releases of IL-8 and TNF-α in rats with traumatic hemorrhagic shock.
ObjectiveTo investigate the relationship between the expression of IL-8 protein in triple negative breast cancer (TNBC) and clinicopathological features and survival prognosis.MethodsThe expression of IL-8 protein in 80 cases of TNBC was detected by immunohistochemical staining, and the relationship between the expression of IL-8 protein and clinicopathological features and prognosis of TNBC patients was analyzed by χ2 test, log-rank test, and Cox proportional hazards regression.ResultsIn 80 TNBC patients, the high expression of IL-8 protein accounted for 22.5% (18/80). The expression level of IL-8 protein in TNBC tumor tissue was correlated with T stage, clinical stage, Ki-67 expression, WHO grade and lymph node metastasis (P<0.05). However, it was not related to age, menopausal status, pathological type of tumor and whether they had received neoadjuvant chemotherapy (P>0.05). The results of log-rank analysis showed that the disease-free survival rate (DFS) of high expression group of IL-8 protein was poor than that of low expression group of IL-8 protein (P<0.05). Multivariate Cox proportional hazards regression analysis showed that the expression of IL-8 protein was an independent factor affecting the survival and prognosis of TNBC patients [HR=1.180, 95%CI (1.001, 1.391), P=0.049]. The prognosis of TNBC patients with high expression of IL-8 protein was poor.ConclusionThe expression level of IL-8 protein is an independent risk factor affecting the survival and prognosis of patients with TNBC.
Objective To investigate the expression of double-stranded DNA (dsDNA), citrulline histone 3 (CitH3), myeloperoxidase-DNA (MPO-DNA), IL-8 and IL-33 in plasma of patients with chronic obstructive pulmonary disease (COPD) and their clinical significance. Methods Forty patients with acute exacerbation COPD (AECOPD) who were hospitalized in The First Affiliated Hospital of Shihezi University School of Medicine from October 2020 to May 2021 were recruited in the AECOPD group, and recruited in the stable COPD group when they entered the stable stage. In the same period, forty healthy individuals were recruited in the control group. General informations including pulmonary function and peripheral blood were collected from each subject. Plasma levels of CitH3, MPO-DNA, interleukin (IL)-8 and IL-33 were measured by enzyme linked immunosorbent assay and plasma levels of dsDNA were measured by PicoGreen fluorescent dye quantitative analysis. Results The levels of dsDNA, CitH3, MPO-DNA, IL-8 and IL-33 in the AECOPD group were higher than those in the stable group and the control group, with statistical significance (P<0.05), and the levels of dsDNA, CitH3, MPO-DNA and IL-33 in the stable group were higher than those in the control group, with statistical significance (P<0.05) . The levels of CitH3, MPO-DNA, IL-33 and IL-8 in the AECOPD group were positively correlated with COPD assessment test (CAT) score. MPO-DNA and IL-8 were positively correlated with CAT score, MPO-DNA was negatively correlated with FEV1%pred, CitH3 was negatively correlated with FEV1/FVC. The levels of IL-8 and dsDNA, CitH3 were positively correlated with the levels of MPO-DNA in the AECOPD group, and positively correlated with the levels of IL-8 and dsDNA in the stable group, but not with CitH3 and MPO-DNA. The levels of IL-33 and IL-8, dsDNA, CitH3, MPO-DNA were positively correlated in the AECOPD group, but not in the stable group. Conclusions The levels of neutrophil extracellular traps (NETs), IL-8 and IL-33 in plasma of COPD patients were increased, and the levels of NETs were correlated with pulmonary function, CAT score, IL-33 and IL-8. NETs may be involved in the development of COPD.
Objective Investigate zinc finger protein 36 (ZFP36) and zinc finger protein 36L1 (ZFP36L1) expression in peripheral blood of patients with chronic obstructive pulmonary disease (COPD). Methods Peripheral blood samples were collected from 42 individuals with acute exacerbation of COPD (AECOPD), 21 with stable COPD, and 18 healthy participants. The levels of ZFP36 and ZFP36L1 proteins and mRNA expressions were evaluated using ELISA and qPCR techniques. Difference in expression levels among the three groups was examined. Spearman analysis and receiver operating characteristic (ROC) curve were carried out for assessment of diagnostic and predictive value of FP36 and ZFP36L1 for COPD and AECOPD. Results Compared with the healthy group, ZFP36L1 protein expression was downregulated in the COPD stable group. ZFP36 protein expression was downregulated in the AECOPD group compared with the COPD stable group. Similar differences were observed in mRNA expression levels. ZFP36 and ZFP36L1 levels were negatively correlated with inflammatory markers. ZFP36 levels were positively correlated with ZFP36L1 and lung function, and negatively correlated with smoking index, modified Medical Research Council score, occurrence of respiratory failure during hospitalization, exacerbation frequency within 3 months, and total hospitalizations. The area under the curve (AUC) for diagnosing AECOPD using ZFP36 was 0.980, with sensitivity of 95.2% and specificity of 90.5%. When combined with FEV1%pred, the AUC improved to 0.985, with sensitivity of 92.9% and specificity of 100%. For predicting post-discharge exacerbations in AECOPD when combined with neutrophil-to-lymphocyte ratio (NLR), sensitivity of ZFP36 alone was 66.7% and specificity was 88.9%. The AUCs for diagnosing COPD using ZFP36, ZFP36L1, and interleukin-8 (IL-8) were 0.889, 0.989, and 0.981, respectively. The sensitivities were 61.9%, 90.5%, and 95.2%, and specificities were 100%, 100%, and 94.4%, respectively. Conclusions Peripheral blood ZFP36 has good diagnostic value for AECOPD. Combined with FEV1%pred, it can further increase diagnostic value. As a predictive indicator for frequent exacerbations within 3 months of discharge in COPD patients, its predictive sensitivity and specificity are superior to inflammatory markers such as NLR. ZFP36 exhibits anti-inflammatory effects in AECOPD. Peripheral blood ZFP36L1 has good diagnostic value for COPD.